Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03426124 · ClinicalTrials.gov registry record
An International Pulmonary Embolism Registry Using EKOS
A clinical trial, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- 1,480
- Enrollment target
NCT03426124: Completed study, sponsored by Boston Scientific Corporation.
NCT03426124 is a clinical trial that has completed, run by Boston Scientific Corporation. The registered enrollment target is 1,480 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03426124 has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- 1,480 participants
- Enrollment target
Study Summary
This registry is designed to understand acoustic pulse thrombolysis (APT) treatment regimens used as standard of care globally for pulmonary embolism. The registry will include individuals who have already received the APT treatment and those that will undergo APT treatment.
Primary Outcome
Difference (percent change) in the measurement of the right ventricular to left ventricular diameters (RV/LV) ratio as measured on baseline echocardiogram to post-procedure echocardiogram (24-48 hours post initiation of therapy).
Interventions
- DEVICE EkoSonic Endovascular System with thrombolytic
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,480 participants |
| Start Date | 2018-03-01 |
| Est. Completion | 2020-09-30 |
What the finished NCT03426124 record still lists
NCT03426124 is an observational study that tracks outcomes without assigning an intervention. Its 1,480 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which EkoSonic Endovascular System with thrombolytic is the first listed.
NCT03426124 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03426124 about?
NCT03426124 is a clinical study titled "An International Pulmonary Embolism Registry Using EKOS". This registry is designed to understand acoustic pulse thrombolysis (APT) treatment regimens used as standard of care globally for pulmonary embolism. The registry will include individuals who have already received the APT treatment and those that will undergo APT treatment.
What is the current status of trial NCT03426124?
This trial is currently completed. The enrollment target is 1,480 participants. The study started on 2018-03-01. Estimated completion is 2020-09-30.
What interventions are being tested in trial NCT03426124?
The interventions under investigation include: EkoSonic Endovascular System with thrombolytic (DEVICE).
Who is sponsoring clinical trial NCT03426124?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05869552 · 1,485 participants · NA
Preventing Suicide Among Sexual and Gender Diverse Young Adults in Primary Care
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
- NCT01050504 · 1,500 participants
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI